Advanced-stage endometrial and cervical cancers are associated with poor outcomes despite contemporary advances in surgical techniques and therapeutics. Recent clinical trial results have led to a shift in the treatment paradigm for both malignancies, where immunotherapy is now incorporated in the upfront setting for most patients with advanced endometrial and cervical cancers as the standard of care. Impressive response rates have been observed, but unfortunately, a subset of patients do not benefit from immunotherapy, and survival remains poor. Continued pre-clinical research and clinical trial development are crucial for our understanding of resistance mechanisms to immunotherapy and maximization of therapeutic efficacy. In this setting, syngeneic models are preferred over xenograft models as they allow for evaluation of the tumor-immune interaction in an immunocompetent host, most closely mimicking the tumor-immune interaction in human cancer patients. Unfortunately, significant disparities exist regarding syngeneic models in gynecologic malignancy, where queries from multiple large bioscience companies confirm no commercial availability of endometrial or cervical cancer syngeneic cell lines. Few published data exist regarding the recent development of several endometrial and cervical cancer syngeneic cell lines, warranting further investigation. Closing the disparity gap for pre-clinical models in endometrial and cervical cancer will support physician-scientists, basic and translational researchers, and clinical trialists who are dedicated to improving outcomes for our patients with advanced disease and poor prognosis.

中文翻译：

---

弥合从实验室到临床的差距：呼吁利用体内临床前模型来推进子宫内膜癌和宫颈癌免疫肿瘤学研究

尽管当代手术技术和治疗方法取得了进步，但晚期子宫内膜癌和宫颈癌仍与不良预后相关。最近的临床试验结果导致这两种恶性肿瘤的治疗模式发生了转变，免疫疗法现已纳入大多数晚期子宫内膜癌和宫颈癌患者的前期设置中，作为护理标准。已经观察到了令人印象深刻的反应率，但不幸的是，一部分患者没有从免疫治疗中受益，并且生存率仍然很低。持续的临床前研究和临床试验开发对于我们了解免疫疗法的耐药机制和最大化治疗效果至关重要。在这种情况下，同基因模型优于异种移植模型，因为它们允许评估免疫活性宿主中的肿瘤-免疫相互作用，最接近地模拟人类癌症患者中的肿瘤-免疫相互作用。不幸的是，妇科恶性肿瘤的同基因模型存在显着差异，多家大型生物科学公司的询问证实子宫内膜癌或宫颈癌同基因细胞系没有商业可用性。关于几种子宫内膜癌和宫颈癌同基因细胞系的最新发展，已发表的数据很少，值得进一步研究。缩小子宫内膜癌和宫颈癌临床前模型的差异将为致力于改善晚期疾病和不良预后患者的结果的医师科学家、基础和转化研究人员以及临床试验人员提供支持。